Pharmacotherapeutic guideline for pain management, first revision, October 2007;Farmacotherapeutische richtlijn Pijnbestrijding: Eerste herziening, Oktober 2007

Huisarts en Wetenschap

Volumn 50, Issue 12, 2007, Pages 601-615

  Verduijn, M M ^a   Folmer, H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIURETIC AGENT; DOMPERIDONE; DULOXETINE; FENTANYL; IBUPROFEN; LITHIUM; METOCLOPRAMIDE; MISOPROSTOL; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OMEPRAZOLE; OPIATE DERIVATIVE; PARACETAMOL; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; UNINDEXED DRUG;

CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; NEUROPATHIC PAIN; PAIN; PRACTICE GUIDELINE; REVIEW; TREATMENT PLANNING; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 39749200059     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. Bij verwijzingen naar NHG-producten: zie http://www.nhg.org.
2. Ahmedzai S. New approaches to pain control in patients with cancer. Eur J Cancer 1997a;33 Suppl 6:S8-14.
3. Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J 2005;118:U1755.
4. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8.
5. Alper BS, Lewis PR. Treatment of postherpetic neuralgia: a systematic review of the literature. J Fam Pract 2002;51:121-8.
6. Anonymus. For neuropathic pain, optimize opioids. J Support Oncol 2006;4:95-6.
7. Aronson JK. Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 15th ed. Amsterdam: Elsevier, 2006.
8. Aronson MD, Nonsteroidal anti-inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Clin Ther 1997;19:420-32.
9. Bateman DN, Kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients. BMJ 1995;310:817-8.
10. Beck DH, Schenk MR, Hagemann K, Doepfmer UR, Kox WJ. The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: a double-blinded, randomized study. Anesth Analg 2000;90:431-6.
11. Bennetto L, Patel NK, Fuller G. Trigeminal neuralgia and its management. BMJ 2007;334:201-5.
12. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180-6.
13. Bijl D. Tramadol: onthouding en risico van afhankelijkheid. Geneesmiddelenbulletin 2007;41:50.
14. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329:1317.
15. Boer A. Hoe nu verder met COX-2-remmers. Geneesmiddelenbulletin 2005;39:121-9.
16. Bolesta S, Haber SL. Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann Pharmacother 2002;36:331-3.
17. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2.
18. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991;47:644-66.
19. Brouwers JRBJ, Delhaas EM. Medicamenteuze behandeling van chronische pijn bij volwassenen. Geneesmiddelenbulletin 1998;32:111-8.
20. Brune K. Is there a rational basis for the different spectra of adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs)? Drugs 1990;40 Suppl 5:12-5.
21. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006;99:132-40.
22. Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81.
23. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya TR, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909-17.
24. Carter KA. Heat-associated increase in transdermal fentanyl absorption. Am J Health Syst Pharm 2003;60:191-2.
25. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006;3:CD005522.
26. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87.
27. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
28. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;369:1621-6.
29. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20:1419-28.
30. College ter Beoordeling van Geneesmiddelen, Balans werkzaamheid/risico's van niet-selectieve NSAID's blijft na herbeoordeling positief. 2006. http://www.cbg-meb.nl/nl/nieuws/index.htm, geraadpleegd juni 2007.
31. Collins SL, Moore RA, McQuayHJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000;20:449-58.
32. Commissie Farmaceutische Hulp. Farmacotherapeutisch Kompas 2007. Amstelveen: College voor zorgverzekeringen, 2007.
33. Conway BR, Fogarty DG, Nelson WE, Doherty CC. Opiate toxicity in patients with renal failure. BMJ 2006;332:345-6.
34. Crul BJP. Achtergronden en diagnostiek van pijn. Bijblijven 2006;22:5-10.
35. De Craen AJ, Di Giuseppe G, Lampe-Schoenmaeckers JE, Kessels AG, Kleijnen J. Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. BMJ 1996;313:321-5.
36. De Graeff A, Verhagen EH, Besse TC, Crul BJP, Krol RJA. Richtlijn pijn. In: De Graeff A, Hesselmann GM, Krol RJA, Kuyper MB, Verhagen EH, Vollaard EJ, editors. Palliatieve zorg. Richtlijnen voor de praktijk. Utrecht: Vereniging van Integrale Kankercentra, 2006. p. 565-621.
37. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619.
38. Del Tacca M, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability of meloxicam, a cox-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Investig 2002;22:799-818.
39. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.
40. Dobecki DA, Schocket SM, Wallace MS, Update on pharmacotherapy guidelines for the treatment of neuropathic pain. Current Pain and Headache Reports 2006;10:185-90.
41. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. BMJ 1998;317:526-30.
42. Eddleston M, Buckley N. Paracetamol (acetaminophen) poisoning. Clinical Evidence 2000;4:775-80.
43. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994;12:2756-65.
44. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD006146.
45. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
46. Enting RH, Wilms EB, Vecht CJ. Medicamenteuze behandeling van neuropatische pijn. Pharmaceutisch Weekblad 2000;135:1420-4.
47. Enting RH, Van der Rijt CCD, Wilms EB. Behandeling van pijn bij kanker met systemisch toegediende opioïden. Ned Tijdschr Geneeskd 2001;950-4.
48. Expert Working Group of the European Association for Palliative Care. Morphine in cancer pain: modes of administration. BMJ 1996;312:823-6.
49. Frolich MA, Giannotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 2001;93:647-8.
50. Garcia Rodriguez LA, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005;3:17.
51. Garner S, Fidan D, Frankish R, Judd M, Shea B, Towheed T, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2002;CD003831.
52. Geerlings SE, Hoepelman IM. Farmacotherapie van herpes zoster en postherpetische neuralgie. Geneesmiddelenbulletin 1997;31:53-8.
53. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.
54. Golden BD, Abramson SB. Selective cyclooxygenase-2 inhibitors. Rheum Dis Clin North Am 1999;25:359-78.
55. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
56. Gotzsche PC. Non-steroidal anti-inflammatory drugs. Clinical Evidence 2001;5:800-7.
57. Hahn TW, Mogensen T, Lund C, Schouenborg L, Rasmussen M. High-dose rectal and oral acetaminophen in postoperative patients - serum and saliva concentrations. Acta Anaesthesin Scand 2000;44:302-6.
58. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37:937-45.
59. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
60. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27:1657-63.
61. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2:e164.
62. Henry D, Lim LL, Garcia Rodriguez LA, Perez GS, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
63. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
64. Hollingshead J, Duhmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006;3:CD003726.
65. Holmer PP, Jakobsson J, Owall A, Plasma concentrations following repeated rectal or intravenous administration of paracetamol after heart surgery. Acta Anaesthesiol Scand 2006;50:673-7.
66. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004;329:948.
67. Howell TK, Patel D. Plasma paracetamol concentrations after different doses of rectal paracetamol in older children A comparison of 1 g vs. 40 mg x kg(-1). Anaesthesia 2003;58:69-73.
68. Inturrisi CE. Management of cancer pain. Pharmacology and principles of management. Cancer 1989;63:2308-20.
69. Jackson KC. Pharmacotherapy for neuropathic pain. Pain Pract 2006;6:27-33.
70. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: Stepping up the quality of its evaluation. JAMA 1995;274:1870-3.
71. Jeal W, Benfield P. Transdermal fentanyl: A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997;53:109-38.
72. Jenkins JK, Seligman PJ. US Food en Drug Administration Executive summary report: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risks. U.S.Food and Drug Adminstration. 2005. http://www.fda.gov/cder/drug/infopage/cox2/NSAIDdecision- Memo.pdf, geraadpleegd juni 2007.
73. Jones SC. Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother 2005;39:1249-59.
74. Kahan M, Srivastava A, Wilson L, Mailis-Gagnon A, Midmer D. Opioids for managing chronic non-malignant pain: safe and effective prescribing. Can Fam Physician 2006;52:1091-6.
75. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
76. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. Informatorium Medicamentorum. Den Haag: KNMP, 2007.
77. Kvalsvik O, Borchgrevink PC, Hagen L, Dale O. Randomized, double-blind, placebo-controlled study of the effect of rectal paracetamol on morphine consumption after abdominal hysterectomy. Acta Anaesthesiol Scand 2003;47:451-6.
78. Kwaliteitsinstituut voor de gezondheidszorg CBO. Richtlijn NSAID-gebruik en preventie van maagschade. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO, 2003.
79. Labrecque M, Dostaler LP, Rousselle R, Nguyen T, Poirier S. Efficacy of nonsteroidal anti-inflammatory drugs in the treatment of acute renal colic: A meta-analysis. Arch Intern Med 1994;154:1381-7.
80. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005;118:1271-8.
81. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.
82. Lancaster T, Wareham D, Yaphe J. Postherpetic neuralgia. Clinical Evidence 2002;7:738-46.
83. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
84. Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004;27:411-20.
85. Launay-Vacher V, Karie S, Fau JB, Izzedine H, Deray G. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain 2005;6:137-48.
86. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007;119:157-64.
87. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104-10.
88. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004;329:324.
89. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004;9:571-91.
90. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005;13:888-94.
91. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6.
92. Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004;27:409-16.
93. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004a;5:10.
94. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004b;328:991.
95. McDonald AA, Portenoy RK. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Support Oncol 2006;4:43-52.
96. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
97. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005;CD005180.
98. McQuay H. Opioids in pain management. Lancet 1999;353:2229-32.
99. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27.
100. Mercadante S, Fulfaro F. Alternatives to oral opioids for cancer pain. Oncology (Williston Park) 1999;13:215-20, 225.
101. Merck News. Merck announces voluntary worldwide withdrawal of VIOXX. Merck 2004. http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final. pdf, geraadpleegd juni 2007.
102. Moore A, Collins S, Carroll D, McQuay H. Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain 1997;70:193-201.
103. Moore RA, Tramer MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998;316:333-8.
104. Moore RA, Derry S, Phillips CJ, McQuay HJ. Non-steroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79.
105. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159:1931-7.
106. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
107. Nederlands Bijwerkingen Centrum Lareb. Anafylactische reacties bij NSAID's. Lareb. April 2005. http://www.lareb.nl/documents/mt_nsaid_anafyl.pdf, geraadpleegd juni 2007.
108. O'Neill B, Fallon M. ABC of palliative care. Principles of palliative care and pain control. BMJ 1997;315:801-4.
109. Psaty BM, Weiss NS. NSAID trials and the choice of comparators - questions of public health importance. N Engl J Med 2007;356:328-30.
110. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002;CD003447.
111. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004;CD004847.
112. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56.
113. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
114. Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:837-43.
115. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2000;CD002296.
116. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005;CD005454.
117. Schug SA, Dunlop R, Zech D. Pharmacological management of cancer pain. Drugs 1992;43:44-53.
118. Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67:1792-800.
119. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
120. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
121. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
122. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
123. Sonnett TE, Setter SM, Campbell RK. Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother 2006;6:1629-35.
124. Spiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006;119:448-36.
125. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 2006;118:801-4.
126. Stocker ME, Montgomery JE. Serum paracetamol concentrations in adult volunteers following rectal administration. Br J Anaesth 2001;87:638-40.
127. Stocker ME, Montgomery JE. Rectal paracetamol dosages. A response to 'Plasma paracetamol concentrations after different doses of rectal paracetamol in older children. A comparison of 1 g vs. 40 mg x kg(-1)', Howell TK, Patel D, Anaesthesia 2003;58:69-72. Anaesthesia 2003;58:618.
128. The European Medicines Agency. Opinion of the Committee for Medicinal Products for human use pursuant to article 5(3) of regulation (EC) No 726/2004, for non-selective non steroidal anti-inflammatory drugs (NSAIDs). The European Medicines Agency (EMEA). 18 oktober 2006. http://www.emea.europa.eu/pdfs/human/ opiniongen/nsaids.pdf, geraadpleegd juni 2007.
129. Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev 2000;CD000517.
130. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;CD004257.
131. U.S. Food and Drug Adminstration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. U.S.Food and Drug Adminstration. 2004a. http://www.fda.gov/bbs/topics/news/2004/NEW01122.html, geraadpleegd juni 2007.
132. U.S. Food and Drug Adminstration. FDA Statement on the halting of a clinical trial of the COX 2 inhibitor Celebrex. U.S. Food and Drug Adminstration. 2004b. http://www.fda.gov/cder/drug/infopage/vioxx, geraadpleegd juni 2007.
133. Van den Bernt BJ, Benraad HB, Rasker JJ. Cardiovasculaire en gastro-intestinale risico's bij selectieve en niet-selectieve NSAID's. Ned Tijdschr Geneeskd 2007;151:1062-7.
134. Van der Marel CD, Van Lingen RA, Pluim MA, Scoones G, Van Dijk M, Vaandrager JM, et al. Analgesic efficacy of rectal versus oral acetaminophen in children after major craniofacial surgery. Clin Pharmacol Ther 2001;70:82-90.
135. Van Kleef M, Vreeling FW. Pijn en pijnbehandeling. 3rd ed. Maastricht: Universitaire Pers, 1999.
136. Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Different risks for NSAID-induced anaphylaxis. Ann Pharmacother 2002;36:24-9.
137. Van Seventer R., Feister HA, Young JP, Jr., Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22:375-84.
138. Vecht CJ, Alting van Geusau RB. Oorzaken van pijn uitgaande van het perifere zenuwstelsel. Ned Tijdschr Geneeskd 1990a;134:59-63.
139. Vecht CJ, Alting van Geusau RB. Medicamenteuze behandeling van pijn uitgaande van het perifere zenuwstelsel. Ned Tijdschr Geneeskd 1990b;134:63-8.
140. Vecht CJ, Sillevis Smitt PA. Transdermale opioidtoediening: de pijnpleister. Ned Tijdschr Geneeskd 1997;141:821-3.
141. Verduijn MM, Folmer H. NHG-Standpunt over de maximum dagdosering van paracetamol voor langdurig gebruik bij benigne aandoeningen. Utrecht: NHG, 2004.
142. Verhave JC, Kramers C, Wetzels JFM. Nauwkeuriger indruk van de nierfunctie. Pharmaceut Weekbl 2007;142:18-21.
143. Vonkeman HE, Brouwers JR, Van de Laar MA. Understanding the NSAID related risk of vascular events. BMJ 2006;332:895-8.
144. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev 2000;CD000142.
145. Watson CP. Management issues of neuropathic trigeminal pain from a medical perspective. J Orofac Pain 2004;18:366-73.
146. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003;146:591-604.
147. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20.
148. Whittle BJ. COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. GUT 2000;47:320-5.
149. Wienecke T, Gotzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2004;CD003789.
150. Wiffen PJ, Edwards JE, Barden J, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev 2003;CD003868.
151. Wiffen PJ, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005a;CD001133.
152. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev 2005b;CD005451.
153. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005c;CD005452.
154. Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev 2007;CD006044.
155. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
156. Zakrezewska JM, Lopez BG. Trigeminal neuralgia. Clinical Evidence 2006;15:1-2.